(Total Views: 225)
Posted On: 05/18/2022 12:33:38 PM
Post# of 27
Thomas Smeenk of Hemostemix HMTXF talks about market reaction to successful litigation settlement
In the interview, which can also be viewed in full on the InvestorIntel YouTube channel ( click here ), Thomas Smeenk talks about Hemostemix’s portfolio of autologous stem cell therapies that uses patient’s own blood to save limbs from amputation, treat heart diseases and other conditions of ischemia. With 91 patents issued worldwide, Thomas says that with the successful return of all of its intellectual property and clinical trial data, Hemostemix is now cleared to continue to move forward.
In the interview, which can also be viewed in full on the InvestorIntel YouTube channel ( click here ), Thomas Smeenk talks about Hemostemix’s portfolio of autologous stem cell therapies that uses patient’s own blood to save limbs from amputation, treat heart diseases and other conditions of ischemia. With 91 patents issued worldwide, Thomas says that with the successful return of all of its intellectual property and clinical trial data, Hemostemix is now cleared to continue to move forward.
(0)
(0)
